Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease
Open accessThe DOI matches its Crossref record; 49 of the 50 references it cites were found in a registry or an index.
Abstract
Nonalcoholic fatty liver disease (NAFLD) is characterized by the accumulation of excess liver triacylglycerol (TAG), inflammation, and liver damage. The goal of the present study was to directly quantify the biological sources of hepatic and plasma lipoprotein TAG in NAFLD. Patients (5 male and 4 female; 44 +/- 10 years of age) scheduled for a medically indicated liver biopsy were infused with and orally fed stable isotopes for 4 days to label and track serum nonesterified fatty acids (NEFAs), dietary fatty acids, and those derived from the de novo lipogenesis (DNL) pathway, present in liver tissue and lipoprotein TAG. Hepatic and lipoprotein TAG fatty acids were analyzed by gas chromatography/mass spectrometry. NAFLD patients were obese, with fasting hypertriglyceridemia and hyperinsulinemia. Of the TAG accounted for in liver, 59.0% +/- 9.9% of TAG arose from NEFAs; 26.1% +/- 6.7%, from DNL; and 14.9% +/- 7.0%, from the diet. The pattern of labeling in VLDL was similar to that in liver, and throughout the 4 days of labeling, the liver demonstrated reciprocal use of adipose and dietary fatty acids. DNL was elevated in the fasting state and demonstrated no diurnal variation. These quantitative metabolic data document that both elevated peripheral fatty acids and DNL contribute to the accumulation of hepatic and lipoprotein fat in NAFLD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Sarcopenic obesity seems to impair insulin signaling in hepatocytes, resulting in increased de novo hepatic lipogenesis and inhibited hepatic β-oxidation [141].”
From Sarcopenic obesity, insulin resistance, and their implications in cardiovascular and metabolic consequences (2020) · cites this paper as [141]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Of note, although the major source of hepatocellular triglycerides are adipose tissue-derived NEFA, the rate of hepatic de novo lipogenesis is also much greater in MASLD, further contributing to intrahepatic lipid accumulation [17].”
From Obesity and MASLD: Is weight loss the (only) key to treat metabolic liver disease? (2024) · cites this paper as [17]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Remarkably, the major fraction of hepatocellular triglycerides in people with obesity and MASLD is not derived from non-esterified fatty acids (NEFA) provided by dietary lipids, but from circulating NEFA released from adipose tissue [17].”
From Obesity and MASLD: Is weight loss the (only) key to treat metabolic liver disease? (2024) · cites this paper as [17]
In the citing paper
“In individuals with MASLD and obesity, hepatic TG is reported to derive approximately 59% from circulating FFAs, 26% from DNL, and 15% from dietary sources [67].”
From Hepatic Insulin Resistance and Steatosis in Metabolic Dysfunction-Associated Steatotic Liver Disease: New Insights into Mechanisms and Clinical Implications (2025) · cites this paper as [67]
In the citing paper
“IHTG was composed mainly of FFAs from SAT lipolysis (∼60%) and, to a lesser extent, FFAs from DNL (∼25%) or diet (∼15%).”
From Lipid metabolism in MASLD and MASH: From mechanism to the clinic (2024) · cites this paper as [23]
3 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A SIMPLE METHOD FOR THE ISOLATION AND PURIFICATION OF TOTAL LIPIDES FROM ANIMAL TISSUES
Folch, J., Lees, M., & Stanley, G. H. S. (1957) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)64849-5 · Cited by 65,189
Matthews, D. R., Hosker, J. P., Rudenski, A. S., Naylor, B. A., Treacher, D. F., & Turner, R. C. (1985) · Diabetologia · doi:10.1007/bf00280883 · Cited by 31,502
Toprak, O., Kurt, H., Sarı, Y., Şarkış, C., Us, H., & Kırık, A. (2017) · Kidney and Blood Pressure Research · doi:10.1159/000468530 · Cited by 29,627
SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver
Horton, J. D., Goldstein, J. L., & Brown, M. S. (2002) · Journal of Clinical Investigation · doi:10.1172/jci15593 · Cited by 4,794 · cited 1×
“Given previous observations of higher fed-state DNL (23) and the known stimulatory effect of insulin on fatty acid synthesis (24), we were surprised that fed-state lipogenesis assessed at 1500 in tTRL TAG did not differ from values obtained in the fasting Figure 1 Model of lipid flux through the liver.”
ResultSREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver
Horton, J. D., Goldstein, J. L., & Brown, M. S. (2002) · Journal of Clinical Investigation · doi:10.1172/jci0215593 · Cited by 4,092
Ludwig, J., Viggiano, T. R., McGill, D. B., & Ott, B. J. (1980) · Mayo Clinic Proceedings · doi:10.1016/s0025-6196(24)00530-5 · Cited by 2,903
Nonalcoholic Fatty Liver Disease
Marchesini, G., Brizi, M., Bianchi, G., Tomassetti, S., Bugianesi, E., Lenzi, M., McCullough, A. J., Natale, S., Forlani, G., & Melchionda, N. (2001) · Diabetes · doi:10.2337/diabetes.50.8.1844 · Cited by 2,581
Nonalcoholic steatohepatitis: association of insulin resistance and mitochondrial abnormalities
Sanyal, A. J., Campbell–Sargent, C., Mirshahi, F., Rizzo, W. B., Contos, M. J., Sterling, R. K., Luketic, V. A., Shiffman, M. L., & Clore, J. N. (2001) · Gastroenterology · doi:10.1053/gast.2001.23256 · Cited by 2,078 · cited 2×
“Insulin resistance has been shown to be associated with dysregulation of adiposederived fatty acid flux in the fasting state (10–12), and strong evidence exists demonstrating that in NAFLD patients, insulin does not suppress adipose tissue lipolysis to the same extent that it does in healthy individuals (13).”
BackgroundAssociation of nonalcoholic fatty liver disease with insulin resistance
Marchesini, G., Brizi, M., Morselli-Labate, A. M., Bianchi, G., Bugianesi, E., McCullough, A. J., Forlani, G., & Melchionda, N. (1999) · The American Journal of Medicine · doi:10.1016/s0002-9343(99)00271-5 · Cited by 1,568
Dixon, J. B., Bhathal, P. S., & O'Brien, P. E. (2001) · Gastroenterology · doi:10.1053/gast.2001.25540 · Cited by 1,360 · cited 6×
“Dixon, J.B., Bhathal, P.S., and O’Brien, P.E. 2001.”
Influential
Research works printed but not linked: 6
- Donnelly, 2004, Diabetes., 56, A53
- 10.2337/diabetes.53.3.521 · DOI · Paper page
- Barrows, 2004, Diabetes., 56, A1388
- Timlin, 2004, Diabetes., 56, A338
- Baar, 2005, Am. J. Physiol., 288, E187
- Hellerstein, 1993, Am. J. Physiol., 265, E814
Cited by
Items 201–300 of 1,038
Recent insights on the role of cholesterol in non-alcoholic fatty liver disease
Arguello, G., Balboa, E., Arrese, M., & Zanlungo, S. (2015) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2015.05.015 · Cited by 306
Moon, Y.-A., Liang, G., Xie, X., Frank-Kamenetsky, M., Fitzgerald, K., Koteliansky, V., Brown, M. S., Goldstein, J. L., & Horton, J. D. (2012) · Cell Metabolism · doi:10.1016/j.cmet.2011.12.017 · Cited by 320
“Deletion of SREBP-1c Only Partially Reduces Liver Fat in ob/ob Mice In humans and mice with insulin resistance and hepatic steatosis, SREBP-1c levels and FA synthesis rates are elevated in liver (Donnelly et al., 2005; Higuchi et al., 2008; Shimomura et al., 1999a).”
Bricambert, J., Miranda, J., Benhamed, F., Girard, J., Postic, C., & Dentin, R. (2010) · Journal of Clinical Investigation · doi:10.1172/jci41624 · Cited by 300
Dietary fructose in nonalcoholic fatty liver disease
Vos, M. B., & Lavine, J. E. (2013) · Hepatology · doi:10.1002/hep.26299 · Cited by 314
“(measured by percent of plasma very low density lipoprotein-triglyceride [VLDL-TG]) and DNL fails to increase postprandially in the pattern of healthy individuals.(14) Lipid dysregulation in NAFLD also includes increased VLDL secretion.”
BackgroundInfluentialDietary Sugars Stimulate Fatty Acid Synthesis in Adults3
Parks, E. J., Skokan, L. E., Timlin, M. T., & Dingfelder, C. S. (2008) · The Journal of Nutrition · doi:10.1093/jn/138.6.1039 · Cited by 316
“This robust increase in de novo lipogenesis postprandially in healthy subjects, in contrast to the lack of an observed increase in obese patients with fatty liver (35), suggests that a significant increase in fatty acid synthesis after CHO consumption can be used as one characteristic to test for metabolic flexibility…”
BackgroundSelf-citationDe novo lipogenesis in human fat and liver is linked to ChREBP-β and metabolic health
Eissing, L., Scherer, T., Tödter, K., Knippschild, U., Greve, J. W., Buurman, W. A., Pinnschmidt, H. O., Rensen, S. S., Wolf, A. M., Bartelt, A., et al. (2013) · Nature Communications · doi:10.1038/ncomms2537 · Cited by 301
Fructose: Metabolic, Hedonic, and Societal Parallels with Ethanol
Lustig, R. H. (2010) · Journal of the American Dietetic Association · doi:10.1016/j.jada.2010.06.008 · Cited by 311
Dowman, J. K., Tomlinson, J. W., & Newsome, P. N. (2011) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2010.04556.x · Cited by 312
“Hyperinsulinaemia also promotes hepatic de novo lipogenesis, which is markedly increased in NAFLD patients compared with normal individuals.(9) It is now recognised that FFA promote insulin resistance, inflammation and oxidative stress, 11 and thus rather than being harmful, hepatic triglyceride accumulation may actua…”
Nonalcoholic steatohepatitis: the role of peroxisome proliferator-activated receptors
Francque, S., Szabo, G., Abdelmalek, M. F., Byrne, C. D., Cusi, K., Dufour, J.-F., Roden, M., Sacks, F., & Tacke, F. (2021) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-020-00366-5 · Cited by 316
Metabolism of triglyceride-rich lipoproteins in health and dyslipidaemia
Borén, J., Taskinen, M.-R., Björnson, E., & Packard, C. J. (2022) · Nature Reviews Cardiology · doi:10.1038/s41569-022-00676-y · Cited by 315
The role of oxidative stress in non-alcoholic steatohepatitis
Koek, G. H., Liedorp, P. R., & Bast, A. (2011) · Clinica Chimica Acta · doi:10.1016/j.cca.2011.04.013 · Cited by 314
Molecular aspects of fructose metabolism and metabolic disease
Herman, M. A., & Birnbaum, M. J. (2021) · Cell Metabolism · doi:10.1016/j.cmet.2021.09.010 · Cited by 290
AISF position paper on nonalcoholic fatty liver disease (NAFLD): Updates and future directions
Lonardo, A., Nascimbeni, F., Targher, G., Bernardi, M., Bonino, F., Bugianesi, E., Casini, A., Gastaldelli, A., Marchesini, G., Marra, F., et al. (2017) · Digestive and Liver Disease · doi:10.1016/j.dld.2017.01.147 · Cited by 306
Natural history and progression of metabolic dysfunction-associated steatotic liver disease
Hagström, H., Shang, Y., Hegmar, H., & Nasr, P. (2024) · The Lancet Gastroenterology & Hepatology · doi:10.1016/s2468-1253(24)00193-6 · Cited by 310
Hepatic glucose and lipid metabolism
Jones, J. G. (2016) · Diabetologia · doi:10.1007/s00125-016-3940-5 · Cited by 296
“In humans, elevated lipogenic rates were found in insulin-resistant NAFLD patients [39, 40], as well as in healthy individuals following both acute intake as well as longer term consumption of diets made hyperenergetic with excess fructose [41–43].”
BackgroundMarchesini, G., Petta, S., & Dalle Grave, R. (2016) · Hepatology · doi:10.1002/hep.28392 · Cited by 292
“La zo , 2 0 1 0 (6 4 ) R C T w ith in th e”
MethodThe role of the lipogenic pathway in the development of hepatic steatosis
Postic, C., & Girard, J. (2008) · Diabetes & Metabolism · doi:10.1016/s1262-3636(08)74599-3 · Cited by 288
“[11] estimated that, while 60% of TG accumulated in the liver of NAFLD patients originates from NEFA, a little over 10% comes from the diet and almost 30% from de novo lipogenesis.”
BackgroundThe ins and outs of endoplasmic reticulum‐controlled lipid biosynthesis
Jacquemyn, J., Cascalho, A., & Goodchild, R. E. (2017) · EMBO reports · doi:10.15252/embr.201643426 · Cited by 286
“In addition, there is strong evidence that abnormal lipid synthesis is itself the primary driver of ER dysfunction in some human metabolic and obesity-related pathologies [118 – 124].”
Vallianou, N., Christodoulatos, G. S., Karampela, I., Tsilingiris, D., Magkos, F., Stratigou, T., Kounatidis, D., & Dalamaga, M. (2021) · Biomolecules · doi:10.3390/biom12010056 · Cited by 289
Trauner, M., Arrese, M., & Wagner, M. (2010) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2009.10.007 · Cited by 291
ChREBP, a Transcriptional Regulator of Glucose and Lipid Metabolism
Postic, C., Dentin, R., Denechaud, P.-D., & Girard, J. (2007) · Annual Review of Nutrition · doi:10.1146/annurev.nutr.27.061406.093618 · Cited by 283
Evolution of NAFLD and Its Management
Mundi, M. S., Velapati, S., Patel, J., Kellogg, T. A., Abu Dayyeh, B. K., & Hurt, R. T. (2020) · Nutrition in Clinical Practice · doi:10.1002/ncp.10449 · Cited by 285
Preiss, D., & Sattar, N. (2008) · Clinical Science · doi:10.1042/cs20070402 · Cited by 292
Luo, W., Xu, Q., Wang, Q., Wu, H., & Hua, J. (2017) · Scientific Reports · doi:10.1038/srep44612 · Cited by 282
“It has been demonstrated that free fatty acids supplied to the liver accounted for almost two-thirds of lipid accumulation in NAFLD 9,25 .”
Dietary carbohydrates and fats in nonalcoholic fatty liver disease
Yki-Järvinen, H., Luukkonen, P. K., Hodson, L., & Moore, J. B. (2021) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-021-00472-y · Cited by 294
Bo, T., Gao, L., Yao, Z., Shao, S., Wang, X., Proud, C. G., & Zhao, J. (2024) · Cell Metabolism · doi:10.1016/j.cmet.2024.04.006 · Cited by 293
Inflammation as a potential link between nonalcoholic fatty liver disease and insulin resistance
Asrih, M., & Jornayvaz, F. R. (2013) · Journal of Endocrinology · doi:10.1530/joe-13-0201 · Cited by 282
“…fatty acids (FAs) are transported to various organs including liver and skeletal muscle; thereafter, FAs undergo either b-oxidation in the mitochondria or are stored as TGs. Hepatic TG storage mainly originates from lipolysis of TGs released from white adipose tissue (Donnelly et al. 2005).”
BackgroundContribution of adipose tissue and de novo lipogenesis to nonalcoholic fatty liver disease
Tamura, S., & Shimomura, I. (2005) · Journal of Clinical Investigation · doi:10.1172/jci200524930 · Cited by 287
“Approximately 25% of accumulated TAGs in the liver are derived from DNL (2).”
BackgroundInfluentialConnecting mTORC1 signaling to SREBP-1 activation
Bakan, I., & Laplante, M. (2012) · Current Opinion in Lipidology · doi:10.1097/mol.0b013e328352dd03 · Cited by 281
“Kinetic studies revealed that de-novo lipogenesis plays a significant role in the excessive accumulation of hepatic triglycerides in obese humans [57].”
BackgroundAkt2 Is Required for Hepatic Lipid Accumulation in Models of Insulin Resistance
Leavens, K. F., Easton, R. M., Shulman, G. I., Previs, S. F., & Birnbaum, M. J. (2009) · Cell Metabolism · doi:10.1016/j.cmet.2009.10.004 · Cited by 281
“Moreover, the relative contribution of de novo lipogenesis to hepatic triglyceride accumulation has been controversial, though recent data suggest that it might account for as much as 25%–30% of the triglyceride in livers of patients with NAFLD (Donnelly et al., 2005).”
BackgroundRoles of PPARs in NAFLD: Potential therapeutic targets
Tailleux, A., Wouters, K., & Staels, B. (2012) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2011.10.016 · Cited by 282
The role of hepatokines in NAFLD
Stefan, N., Schick, F., Birkenfeld, A. L., Häring, H.-U., & White, M. F. (2023) · Cell Metabolism · doi:10.1016/j.cmet.2023.01.006 · Cited by 282
Non-alcoholic fatty liver disease pathogenesis: The present and the future
Petta, S., Muratore, C., & Craxì, A. (2009) · Digestive and Liver Disease · doi:10.1016/j.dld.2009.01.004 · Cited by 285
“[16] showed that the influx of plasma FFA from adipose tissue to the liver accounts for about 60–80% of the source of intrahepatic fat.”
BackgroundGastaldelli, A., Harrison, S. A., Belfort-Aguilar, R., Hardies, L. J., Balas, B., Schenker, S., & Cusi, K. (2009) · Hepatology · doi:10.1002/hep.23116 · Cited by 285
Liver transplantation using fatty livers: Always feasible?
McCormack, L., Dutkowski, P., El-Badry, A. M., & Clavien, P.-A. (2011) · Journal of Hepatology · doi:10.1016/j.jhep.2010.11.004 · Cited by 281
“Additionally, a defective hepatic export, caused by reduced lipoprotein synthesis or impaired b-oxidation of fatty acids, further increases hepatic triglyceride content [14].”
Qureshi, K. (2007) · World Journal of Gastroenterology · doi:10.3748/wjg.v13.i26.3540 · Cited by 283
Barrows, B. R., & Parks, E. J. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-1709 · Cited by 272
“Lipoprotein fractions with Svedberg unit (Sf) 400 and Sf 60–400 were then isolated as previously described (21).”
MethodSelf-citationPPARs and nonalcoholic fatty liver disease
Liss, K. H. H., & Finck, B. N. (2017) · Biochimie · doi:10.1016/j.biochi.2016.11.009 · Cited by 275
“Fatty acids in circulation and hepatic lipogenesis significantly contribute to accumulation of triglycerides in the liver while dietary lipids also account for a significant proportion of intrahepatic lipids [1,10].”
BackgroundSchwarz, J.-M., Noworolski, S. M., Erkin-Cakmak, A., Korn, N. J., Wen, M. J., Tai, V. W., Jones, G. M., Palii, S. P., Velasco-Alin, M., Pan, K., et al. (2017) · Gastroenterology · doi:10.1053/j.gastro.2017.05.043 · Cited by 266
“Our data suggest that the effect of fructose on liver fat is specific and mediated through reductions in DNL. DNL was originally thought to be a minor metabolic pathway in humans.25 However, increased DNL has been demonstrated in adults with NAFLD.35 Using stable isotopes, Donnelly et al.8 showed that in adults with N…”
MethodStanhope, K. L., & Havel, P. J. (2008) · Current Opinion in Lipidology · doi:10.1097/mol.0b013e3282f2b24a · Cited by 269
Santoro, N., Zhang, C. K., Zhao, H., Pakstis, A. J., Kim, G., Kursawe, R., Dykas, D. J., Bale, A. E., Giannini, C., Pierpont, B., et al. (2012) · Hepatology · doi:10.1002/hep.24806 · Cited by 263
“The increased GCK activity in the liver is predicted to enhance the glycolytic flux, thus promoting hepatic glucose metabolism and elevating the concentrations of malonyl coenzyme A (CoA), a substrate for de novo lipogenesis (DNL), which may account for about 26% of fat accumulation in the liver.(14) The increase in m…”
BackgroundHepatic triacylglycerol accumulation and insulin resistance
Nagle, C. A., Klett, E. L., & Coleman, R. A. (2009) · Journal of Lipid Research · doi:10.1194/jlr.r800053-jlr200 · Cited by 272
Adipokines in NASH: Postprandial Lipid Metabolism as a Link Between Adiponectin and Liver Disease *
Musso, G., Gambino, R., Durazzo, M., Biroli, G., Carello, M., Fagà, E., Pacini, G., De Michieli, F., Rabbione, L., Premoli, A., et al. (2005) · Hepatology · doi:10.1002/hep.20896 · Cited by 271
Free radical biology for medicine: learning from nonalcoholic fatty liver disease
Serviddio, G., Bellanti, F., & Vendemiale, G. (2013) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2013.08.174 · Cited by 267
“Patients affected by NAFLD show an increase in both uptake and synthesis [34,35], whereas experimental reduction of lipogenesis, consisting in hepatic expression of malonyl-CoA decarboxylase (MCD) or inhibition of acetyl-CoA carboxylase (ACC), reverses hepatic steatosis [36,37].”
Mechanisms of muscle insulin resistance and the cross‐talk with liver and adipose tissue
Silva Rosa, S. C., Nayak, N., Caymo, A. M., & Gordon, J. W. (2020) · Physiological Reports · doi:10.14814/phy2.14607 · Cited by 240
“In a nonalcoholic fatty liver disease (NAFLD), increased re-esterification of circulating fatty acids supplied by adipose insulin resistance is possibly one of the leading causes of increased liver triglyceride (Donnelly et al., 2005).”
BackgroundPathogenesis and treatment of non-alcoholic steatohepatitis and its fibrosis
Lee, K.-C., Wu, P.-S., & Lin, H.-C. (2023) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2022.0237 · Cited by 246
Lipotoxic lethal and sublethal stress signaling in hepatocytes: relevance to NASH pathogenesis
Hirsova, P., Ibrabim, S. H., Gores, G. J., & Malhi, H. (2016) · Journal of Lipid Research · doi:10.1194/jlr.r066357 · Cited by 270
Role of Insulin Resistance and Lipotoxicity in Non-Alcoholic Steatohepatitis
Cusi, K. (2009) · Clinics in Liver Disease · doi:10.1016/j.cld.2009.07.009 · Cited by 266
Gastrointestinal Complications of Obesity
Camilleri, M., Malhi, H., & Acosta, A. (2017) · Gastroenterology · doi:10.1053/j.gastro.2016.12.052 · Cited by 269
Hendriks, D., Brouwers, J. F., Hamer, K., Geurts, M. H., Luciana, L., Massalini, S., López-Iglesias, C., Peters, P. J., Rodríguez-Colman, M. J., Chuva de Sousa Lopes, S., et al. (2023) · Nature Biotechnology · doi:10.1038/s41587-023-01680-4 · Cited by 249
“…a single-nucleotide polymorphism (SNP) in the PNPLA3 gene Article https://doi.org/10.1038/s41587-023-01680-4 those derived from lipolysis of adipose tissue as well as those from spillover of lipoprotein lipase-generated FFAs from chylomicrons; and (3) hepatic DNL using carbohydrate sources 27 .”
BackgroundInfluentialPathogenesis and management issues for non-alcoholic fatty liver disease
Duvnjak, M. (2007) · World Journal of Gastroenterology · doi:10.3748/wjg.v13.i34.4539 · Cited by 264
Longitudinal analysis of murine steatohepatitis model induced by chronic exposure to high‐fat diet
Ito, M., Suzuki, J., Tsujioka, S., Sasaki, M., Gomori, A., Shirakura, T., Hirose, H., Ito, M., Ishihara, A., Iwaasa, H., et al. (2007) · Hepatology Research · doi:10.1111/j.1872-034x.2007.00008.x · Cited by 253
Adipocyte lipolysis: from molecular mechanisms of regulation to disease and therapeutics
Yang, A., & Mottillo, E. P. (2020) · Biochemical Journal · doi:10.1042/bcj20190468 · Cited by 246
Oddy, W. H., Herbison, C. E., Jacoby, P., Ambrosini, G. L., O'Sullivan, T. A., Ayonrinde, O. T., Olynyk, J. K., Black, L. J., Beilin, L. J., Mori, T. A., et al. (2013) · American Journal of Gastroenterology · doi:10.1038/ajg.2013.95 · Cited by 256
Luukkonen, P. K., Dufour, S., Lyu, K., Zhang, X.-M., Hakkarainen, A., Lehtimäki, T. E., Cline, G. W., Petersen, K. F., Shulman, G. I., & Yki-Järvinen, H. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1922344117 · Cited by 249
“One possible fate of FA in the liver is re-esterification, which is the major pathway contributing IHTG in NAFLD (11).”
BackgroundAdvances in Pediatric Nonalcoholic Fatty Liver Disease†
Loomba, R., Sirlin, C. B., Schwimmer, J. B., & Lavine, J. E. (2009) · Hepatology · doi:10.1002/hep.23119 · Cited by 264
Goedeke, L., Bates, J., Vatner, D. F., Perry, R. J., Wang, T., Ramirez, R., Li, L., Ellis, M. W., Zhang, D., Wong, K. E., et al. (2018) · Hepatology · doi:10.1002/hep.30097 · Cited by 259
“BUt INCReaSeS FaStINg plaSMa tRIglyCeRIDeS aND NeFaS To determine the long-term effect of ACC inhibition on glucose and lipid metabolism, male SD rats were fed an HFSD, a model that explores the ability of ACCi to reverse diet-induced NAFLD and insulin resistance by increasing fat oxidation and/or inhibiting DNL.”
BackgroundInfluentialNon-Alcoholic Fatty Liver Disease
Engin, A. (2017) · Advances in Experimental Medicine and Biology · doi:10.1007/978-3-319-48382-5_19 · Cited by 248
Gut microbiota and non-alcoholic fatty liver disease: new insights
Aron-Wisnewsky, J., Gaborit, B., Dutour, A., & Clement, K. (2013) · Clinical Microbiology and Infection · doi:10.1111/1469-0691.12140 · Cited by 248
“Indeed in that context, there is a concomitant increased supply (coming from diet, de novo lipogenesis [58] and adipose tissue) and decreased degradation (via impaired b-oxidation) [57].”
BackgroundMetabolic disturbances in non-alcoholic fatty liver disease
Byrne, C. D., Olufadi, R., Bruce, K. D., Cagampang, F. R., & Ahmed, M. H. (2009) · Clinical Science · doi:10.1042/cs20080253 · Cited by 258
Lipidomic biomarkers and mechanisms of lipotoxicity in non-alcoholic fatty liver disease
Svegliati-Baroni, G., Pierantonelli, I., Torquato, P., Marinelli, R., Ferreri, C., Chatgilialoglu, C., Bartolini, D., & Galli, F. (2019) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2019.05.029 · Cited by 249
Cardio-Metabolic Effects of High-Fat Diets and Their Underlying Mechanisms—A Narrative Review
Wali, J. A., Jarzebska, N., Raubenheimer, D., Simpson, S. J., Rodionov, R. N., & O’Sullivan, J. F. (2020) · Nutrients · doi:10.3390/nu12051505 · Cited by 235
“However, increased re-esterification of fatty acids supplied to the liver from augmented adipose tissue lipolysis also contributes significantly to the liver triglyceride abundance, and this is independent of hepatic insulin signaling [12,94].”
BackgroundThe role of fatty acids in the development and progression of nonalcoholic fatty liver disease
Gentile, C. L., & Pagliassotti, M. J. (2008) · The Journal of Nutritional Biochemistry · doi:10.1016/j.jnutbio.2007.10.001 · Cited by 252
“In this context, it has recently been found in NAFLD patients that a considerable portion of hepatic triglycerides are derived from the diet [101].”
BackgroundKotronen, A., Seppänen-Laakso, T., Westerbacka, J., Kiviluoto, T., Arola, J., Ruskeepää, A.-L., Orešič, M., & Yki-Järvinen, H. (2009) · Diabetes · doi:10.2337/db08-1074 · Cited by 245
“In addition, when estimated using tracer techniques, de novo lipogenesis has been found to be significantly increased in subjects with NAFLD compared with normal subjects (12,15,16).”
BackgroundAthyros, V. G., Mikhailidis, D. P., Didangelos, T. P., Giouleme, O. I., Liberopoulos, E. N., Karagiannis, A., Kakafika, A. I., Tziomalos, K., Burroughs, A. K., & Elisaf, M. S. (2006) · Current Medical Research and Opinion · doi:10.1185/030079906x104696 · Cited by 248
The relation of saturated fatty acids with low-grade inflammation and cardiovascular disease
Ruiz-Núñez, B., Dijck-Brouwer, D. A. J., & Muskiet, F. A. J. (2016) · The Journal of Nutritional Biochemistry · doi:10.1016/j.jnutbio.2015.12.007 · Cited by 245
“The discrepancy between SFA intake and SFA status might derive from the often-overlooked endogenous SFA synthesis (DNL; notably 16:0) from CHO and other precursors, which, in contrast to the widespread believe, may contribute to a sizeable extent to SFA status [29,159].”
BackgroundInfluentialChen, W., Chang, B., Li, L., & Chan, L. (2010) · Hepatology · doi:10.1002/hep.23812 · Cited by 247
“F atty liver disease, especially nonalcoholic fatty liver disease, is characterized by excessive triacylglycerol (TG) accumulation in the liver, and is the most common form of liver disease in western society.(1,2) Although alcohol abuse, obesity, insulin resistance, and diabetes are known to be associated with fatty…”
Highly Purified Eicosapentaenoic Acid Treatment Improves Nonalcoholic Steatohepatitis
Tanaka, N., Sano, K., Horiuchi, A., Tanaka, E., Kiyosawa, K., & Aoyama, T. (2008) · Journal of Clinical Gastroenterology · doi:10.1097/mcg.0b013e31815591aa · Cited by 248
“In steatotic livers, most hepatic triglycerides are derived from circulating FFA released mainly from adipose tissue and from de novo lipogenesis in hepatocytes.(25) It has been reported that EPA administration leads to a reduction of fatty acid synthase expression in white adipose tissues and a resultant decrease in…”
BackgroundCao, J., Dai, D.-L., Yao, L., Yu, H.-H., Ning, B., Zhang, Q., Chen, J., Cheng, W.-H., Shen, W., & Yang, Z.-X. (2012) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-011-1211-9 · Cited by 241
“Indeed, in NAFLD, a large portion of the elevated hepatic triglyceride stores appear to arise from re-esterification of circulating free fatty acids (FFAs) [17], and saturated fatty acids are more toxic than the unsaturated [18] by inducing ER stress and activating UPR in the hepatocytes [6, 19].”
BackgroundBenefits of lifestyle modification in NAFLD
Harrison, S. A., & Day, C. P. (2007) · Gut · doi:10.1136/gut.2006.112094 · Cited by 240
Mitochondrial fatty acid oxidation in obesity
Serra, D., Mera, P., Malandrino, M. I., Mir, J. F., & Herrero, L. (2013) · Antioxidants & Redox Signaling · doi:10.1089/ars.2012.4875 · Cited by 246
“A hallmark of NAFLD is the accumulation of hepatic TGs, which originate in the increased availability of free FAs (FFAs; circulating and from de novo lipogenesis), altered FAO and inadequate synthesis and export of VLDL (37, 55).”
The circadian clock and liver function in health and disease
Mukherji, A., Bailey, S. M., Staels, B., & Baumert, T. F. (2019) · Journal of Hepatology · doi:10.1016/j.jhep.2019.03.020 · Cited by 246
“Increased FFA release from adipocytes due to insulin resistance (51) and conversion of excess carbohydrates to FFA via hepatic de novo lipogenesis (DNL) (52) are two major sources of TG deposition during NAFLD development, in addition to excess caloric intake.”
BackgroundFujita, K., Nozaki, Y., Wada, K., Yoneda, M., Fujimoto, Y., Fujitake, M., Endo, H., Takahashi, H., Inamori, M., Kobayashi, N., et al. (2009) · Hepatology · doi:10.1002/hep.23094 · Cited by 244
Microbiota and Fatty Liver Disease—the Known, the Unknown, and the Future
Lang, S., & Schnabl, B. (2020) · Cell Host & Microbe · doi:10.1016/j.chom.2020.07.007 · Cited by 231
“Accumulation of fat in the liver is a consequence of an increased availability of free fatty acids derived from adipose tissue, which contributes up to 60% of hepatic fat content, while hepatic de novo lipogenesis, is responsible for up to 30% of hepatic fat, with added contribution from dietary lipid intake (Donnelly…”
BackgroundNonalcoholic Fatty Liver Disease: Focus on Lipoprotein and Lipid Deregulation
Fon Tacer, K., & Rozman, D. (2011) · Journal of Lipids · doi:10.1155/2011/783976 · Cited by 231
“Tracer studies in obese humans with NASH demonstrated that 60% of triglycerides in the liver arose from free fatty acids, 25% from de novo lipogenesis, and 15% from the diet [90].”
Paniagua, J. A., de la Sacristana, A. G., Romero, I., Vidal-Puig, A., Latre, J. M., Sanchez, E., Perez-Martinez, P., Lopez-Miranda, J., & Perez-Jimenez, F. (2007) · Diabetes Care · doi:10.2337/dc06-2220 · Cited by 237
Degradation of lipid droplets by chimeric autophagy-tethering compounds
Fu, Y., Chen, N., Wang, Z., Luo, S., Ding, Y., & Lu, B. (2021) · Cell Research · doi:10.1038/s41422-021-00532-7 · Cited by 221
“2 An abnormal accumulation of LDs is involved in many diseases such as obesity, cardiovascular disease, fatty liver disease, and neurodegeneration, 3 – 5 and thus enhancing LD degradation could be desired to treat some of the relevant diseases or provide better health conditions.”
Ectopic lipid storage and insulin resistance: a harmful relationship
Borén, J., Taskinen, M. ‐., Olofsson, S. ‐., & Levin, M. (2013) · Journal of Internal Medicine · doi:10.1111/joim.12071 · Cited by 234
Dongiovanni, P., Anstee, Q., & Valenti, L. (2013) · Current Pharmaceutical Design · doi:10.2174/13816128113199990381 · Cited by 233
“Several lines of evidence support the hypothesis that most of the FFAs accumulated as triglycerides during steatosis derive from increased peripheral lipolysis [16] related to adipose tissue insulin resistance [17], followed by increased lipogenesis induced by hyperinsulinemia and diet.”
BackgroundClinical and Metabolic Characterization of Lean Caucasian Subjects With Non-alcoholic Fatty Liver
Feldman, A., Eder, S. K., Felder, T. K., Kedenko, L., Paulweber, B., Stadlmayr, A., Huber-Schönauer, U., Niederseer, D., Stickel, F., Auer, S., et al. (2017) · American Journal of Gastroenterology · doi:10.1038/ajg.2016.318 · Cited by 239
Bertola, A., Bonnafous, S., Anty, R., Patouraux, S., Saint-Paul, M.-C., Iannelli, A., Gugenheim, J., Barr, J., Mato, J. M., Le Marchand-Brustel, Y., et al. (2010) · PLoS ONE · doi:10.1371/journal.pone.0013577 · Cited by 240
“Inflammation causes adipocyte insulin resistance resulting in increased lipolysis and serum free fatty acids (FFA) flux, alteration of adipokine secretion and consequently hepatic fat accumulation and insulin resistance [7–9].”
BackgroundYang, Z.-X., Shen, W., & Sun, H. (2010) · Hepatology International · doi:10.1007/s12072-010-9202-6 · Cited by 226
“Furthermore, the high level of synthesis was maintained under the conditions of fasting, which suggests that the increase in fatty acid synthesis is one of the essential factors for triglyceride accumulation in liver cells of humans [24, 25 ].”
BackgroundNon-Alcoholic Steatohepatitis: A Review of Its Mechanism, Models and Medical Treatments
Peng, C., Stewart, A. G., Woodman, O. L., Ritchie, R. H., & Qin, C. X. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.603926 · Cited by 225
“Notably, of all TGs found in the liver of NAFLD patients, 59% are derived from plasma FFAs, whereas 15% and 26% are derived from dietary fat and de novo lipogenesis, respectively (Donnelly et al., 2005).”
BackgroundThe Differential Roles of T Cells in Non-alcoholic Fatty Liver Disease and Obesity
Van Herck, M. A., Weyler, J., Kwanten, W. J., Dirinck, E. L., De Winter, B. Y., Francque, S. M., & Vonghia, L. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00082 · Cited by 238
“In the context of NAFLD, it has been estimated that 60% of the hepatic triglycerides originates from adipose tissue lipolysis (15).”
BackgroundObesity, diabetes mellitus, and liver fibrosis
Chiang, D. J., Pritchard, M. T., & Nagy, L. E. (2011) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00426.2010 · Cited by 236
An adipocentric perspective on the development and progression of non-alcoholic fatty liver disease
Lee, E., Korf, H., & Vidal-Puig, A. (2023) · Journal of Hepatology · doi:10.1016/j.jhep.2023.01.024 · Cited by 222
Insulin-independent regulation of hepatic triglyceride synthesis by fatty acids
Vatner, D. F., Majumdar, S. K., Kumashiro, N., Petersen, M. C., Rahimi, Y., Gattu, A. K., Bears, M., Camporez, J.-P. G., Cline, G. W., Jurczak, M. J., et al. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1423952112 · Cited by 235
“Taken together, these results obviate a paradox of selective insulin resistance, because the major source of hepatic lipid synthesis, esterification of preformed fatty acids, is primarily dependent on substrate delivery and largely independent of hepatic insulin action. nonalcoholic fatty liver disease | hepatic insul…”
BackgroundInfluentialFructose as a key player in the development of fatty liver disease
Basaranoglu, M. (2013) · World Journal of Gastroenterology · doi:10.3748/wjg.v19.i8.1166 · Cited by 235
Diabetes and Nonalcoholic Fatty Liver Disease: A Pathogenic Duo
Williams, K. H., Shackel, N. A., Gorrell, M. D., McLennan, S. V., & Twigg, S. M. (2013) · Endocrine Reviews · doi:10.1210/er.2012-1009 · Cited by 233
Pathogenesis of nonalcoholic steatohepatitis
Liu, W., Baker, R. D., Bhatia, T., Zhu, L., & Baker, S. S. (2016) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-016-2161-x · Cited by 221
“Dietary fats, circulating free fatty acids (FFAs) from lipolysis of adipose tissue, and de novo lipogenesis (DNL) are three lipid sources for hepatocytes, contributing to 15, 59, and 26 % of hepatic lipids in NAFLD patients, respectively [53].”
Immunological mechanisms and therapeutic targets of fatty liver diseases
Wang, H., Mehal, W., Nagy, L. E., & Rotman, Y. (2021) · Cellular & Molecular Immunology · doi:10.1038/s41423-020-00579-3 · Cited by 221
Chahil, T. J., & Ginsberg, H. N. (2006) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2006.06.002 · Cited by 233
The role of hepatic fat accumulation in pathogenesis of non-alcoholic fatty liver disease (NAFLD)
Liu, Q., Bengmark, S., & Qu, S. (2010) · Lipids in Health and Disease · doi:10.1186/1476-511x-9-42 · Cited by 229
Pettinelli, P., del Pozo, T., Araya, J., Rodrigo, R., Araya, A. V., Smok, G., Csendes, A., Gutierrez, L., Rojas, J., Korn, O., et al. (2009) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2009.08.015 · Cited by 229
“Up-regulation of liver SREBP-1c is in agreement with the enhanced DNL observed in obesity [20-22], considering that SREBP-1c transcriptionally activates most genes required for hepatic lipogenesis [23], as shown by the 70% increase in FAS expression.”
BackgroundMetabolic aspects in NAFLD, NASH and hepatocellular carcinoma: the role of PGC1 coactivators
Piccinin, E., Villani, G., & Moschetta, A. (2019) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-018-0089-3 · Cited by 231
Sweet Sixteenth for ChREBP: Established Roles and Future Goals
Abdul-Wahed, A., Guilmeau, S., & Postic, C. (2017) · Cell Metabolism · doi:10.1016/j.cmet.2017.07.004 · Cited by 231
“Importantly, ChREBP inhibition in obese and insulin-resistant ob/ob mice, through RNAi or genetic ablation, leads to reversal of hepatic steatosis, providing a direct proof for the involvement of ChREBP in the pathogenesis of NAFLD (Dentin et al., 2006; Iizuka et al., 2006).”
BackgroundBates, J., Vijayakumar, A., Ghoshal, S., Marchand, B., Yi, S., Kornyeyev, D., Zagorska, A., Hollenback, D., Walker, K., Liu, K., et al. (2020) · Journal of Hepatology · doi:10.1016/j.jhep.2020.04.037 · Cited by 230
Metabolic drivers of non-alcoholic fatty liver disease
Bence, K. K., & Birnbaum, M. J. (2021) · Molecular Metabolism · doi:10.1016/j.molmet.2020.101143 · Cited by 221
Obesity-Dependent Metabolic Signatures Associated with Nonalcoholic Fatty Liver Disease Progression
Barr, J., Caballería, J., Martínez-Arranz, I., Domínguez-Díez, A., Alonso, C., Muntané, J., Pérez-Cormenzana, M., García-Monzón, C., Mayo, R., Martín-Duce, A., et al. (2012) · Journal of Proteome Research · doi:10.1021/pr201223p · Cited by 226
Yan, J., Liao, K., Wang, T., Mai, K., Xu, W., & Ai, Q. (2015) · PLOS ONE · doi:10.1371/journal.pone.0129937 · Cited by 224
“More precisely, Donnelly et al.[45] reported that 59% of the TAG that accumulated in the liver of the NAFLD patients originated from NEFAs, and greater than 60% of NEFAs were from adipose tissue.”
Background
Metadata
- Authors
- Donnelly, K. L., Smith, C. I., Schwarzenberg, S. J., Jessurun, J., Boldt, M. D., & Parks, E. J.
- Affiliations
- University of Minnesota (US)
- Corresponding author
- Parks, Elizabeth J.
- Venue
- Journal of Clinical Investigation
- Published
- 2005-05-02
- Volume
- 115
- Issue
- 5
- Pages
- 1343-1351
- ISSN
- 0021-9738 (ISSN-L)
- PMC
- PMC1087172
- OpenAlex
- W1985592156
- Semantic Scholar
- ed7633369ab77ee37699d391fe0fa59627da0df8
- Cited by
- 3,604
- References
- 50
- Citations by year
- 2026: 158 · 2025: 199 · 2024: 230 · 2023: 268 · 2022: 254 · 2021: 264 · 2020: 229 · 2019: 221 · 2018: 222 · 2017: 184 · 2016: 200 · 2015: 185 · 2014: 163 · 2013: 147 · 2012: 127
- FWCI
- 44.79
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Clinical Investigation (publishedVersion)
- PubMed Central (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed (publishedVersion)
- Funders
- American Diabetes Association
- University of Minnesota
- National Institutes of Health (RR00400)
- National Institute of Diabetes and Digestive and Kidney Diseases (R03DK058286)
- National Institute of Arthritis and Musculoskeletal and Skin Diseases (PAR-98-086)
- National Center for Research Resources (M01RR000400)
- Topics
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Lipid metabolism and biosynthesis
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
- Keywords
- non-alcoholic fatty liver disease, hepatic triglycerides, de novo lipogenesis, free fatty acids, VLDL, stable isotope tracers, fatty acid sources, hepatic lipid accumulation, obesity, hypertriglyceridemia, hyperinsulinemia
- MeSH terms
- Adult, Fatty Acids, Fatty Liver, Female, Humans, Lipoproteins, Liver, Male, Middle Aged, Time Factors, Triglycerides, Cholesterol, VLDL
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.